Clinical trial
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment…
NCT00390611 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00390611 |
|---|---|
| Title | Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer |
| Official title | A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Sorafenib, Paclitaxel, Carboplatin |
| Enrollment | 85 |
| Start date | Oct 1, 2006 |
| Primary completion | Jul 1, 2012 |
| Completion | Apr 1, 2014 |
| First posted | Oct 20, 2006 |
| Last update posted | Dec 22, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: